Experimental and clinical psychopharmacology: National Institute on Drug Abuse's clinical research agenda.
Studies of drugs and behavior are a core component of virtually every portfolio within the broad purview of the National Institute on Drug Abuse (NIDA). Moreover, psychopharmacological research is an important vehicle for advancing understanding of how drugs of abuse produce their effects, particularly including addiction. However, as with all major public health issues, simply understanding the issue is not enough. NIDA's psychopharmacology projects, therefore, span basic, clinical, and applied (e.g., medication development) research activities. These include the establishment of a nationwide clinical trials network designed to provide an infrastructure to test both behavioral and psychopharmacological treatments in a real-life practice setting with diverse patients.
Leshner
Alan I
AI
National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland, USA. aleshner@aaas.org
D000163:Acquired Immunodeficiency Syndrome / Q000503:physiopathology / Q000523:psychology; D001521:Behavior Therapy; D016739:Behavior, Addictive / Q000503:physiopathology; D035843:Biomedical Research; D006801:Humans; D009316:National Institutes of Health (U.S.); D011600:Psychopharmacology / Q000639:trends*; D019966:Substance-Related Disorders / Q000188:drug therapy / Q000523:psychology / Q000628:therapy*; D014481:United States